Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339910 · ClinicalTrials.gov registry record · Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
A Phase 3 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT01339910 is a Phase 3 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 272 participants.
The verdict
NCT01339910, a Phase 3 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC) versus reduced intensity conditioning (RIC) regimens.
Interventions
- DRUG Fludarabine and Busulfan
- DRUG Fludarabine and Melphalan
- DRUG Busulfan and Fludarabine
- DRUG Cyclophosphamide and Total Body Irradiation
- DRUG Busulfan and Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339910
The ClinicalTrials.gov registry entry for NCT01339910 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine and Busulfan is the first listed.
NCT01339910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339910 about?
NCT01339910 is a clinical study titled "Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)". The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC) versus reduced intensity conditioni...
What is the current status of trial NCT01339910?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2011-06. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT01339910?
The interventions under investigation include: Fludarabine and Busulfan (DRUG), Fludarabine and Melphalan (DRUG), Busulfan and Fludarabine (DRUG), Cyclophosphamide and Total Body Irradiation (DRUG), Busulfan and Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT01339910?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.